Research On The Relation About R&D Capability And Firm Performance Based On Phar Maceutical Enterprises

With the deepening o f "innovation drive n" concept, enterprises as the backboneof innovation, the influe nce fro m the research and develop ment activity to theperformance of e nterprises and the econo mic develop ment o f the country raisepeople’s attention. Due to the limitations of the data for disclosure of the listedcompa nies and ignoration the factor of the knowledge integration ability, the strongsubjectivity of the selection of R&D data and the incons istency o f statistics ca libermay reduce the credibility of the conclus ion. There fore, it is necessary to use ca liberunified R&D activity data from the microscopic view, and consider the knowledgeintegration capability, us ing the patent applying number as substitutio n variab les,analyze the influence of R&D investme nt and knowledge inte gration ability to theenterprise performa nce simultaneous ly.This study se lected99listed companies as the research object, collected thepane l data from2008to2012, First, this stud y shows that the pharmaceutica lenterprises’ R&D intensity and patent data are obviously on low side; Then R&Dspend ing and patents applied data as exp lanatory variables, two performa nce indexesROE and EPS as expla ined variables, build ing multivariate linear regression model toexamine the relationship about R&D activities、knowledge inte gration capability andenterprise performa nce; It shows that there is no significant correlation between R&Dand enterprise performance and as substitution variab le of knowledge inte grationcapability, total number of patents app lied had significa nt correlation with enterpriseperformance; The patents of d ifferent qua lity had different correlation withperformance: invention patents can effectively enhance the enterprise’s ROE and EPS,utility model patents and appearance design patents have no s ignifica nt correlationwith enterprise ROE and EPS.From the results of this study we can see, firms sho uld increase R&D spending,improve the e fficie ncy o f R&D into economic bene fits; In additio n, the number ofpatent applications as a substitute of knowledge inte gration capability, has feasib ilityin practice, enterprises should improve its knowledge integration capability,increasing the number of patent applications, at the same time, pay attentio n to qualityof patent applications. To ens ure the healthy deve lopment of med ic ine ma nufacturingindustry, it’s necessary to take measures to protecte and ma nage patents.